These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2130934)

  • 1. Ketanserin: a novel cardiovascular drug.
    Symoens J
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):219-24. PubMed ID: 2130934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies.
    Clement DL; Duprez D
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S89-95. PubMed ID: 2446082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related effects of 5-HT2 antagonists.
    Doyle AE
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S29-34. PubMed ID: 1717770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
    Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
    Bühler FR; Amstein R
    Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
    Loschiavo C; Valvo E; Bedogna V; Casagrande P; Graziani MS; Nicoli M; Maschio G
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):455-7. PubMed ID: 2272704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease.
    Apelqvist J; Castenfors J; Larsson J; Stenström A; Persson G
    Int Angiol; 1990; 9(2):120-4. PubMed ID: 2254674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
    De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
    Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of the serotonergic antagonist ketanserin.
    Stott DJ; Robertson JI; Ball SG
    J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin: systemic and regional hemodynamic characterization of its serotonergic and alpha-adrenergic receptor blocking effects in the pithed SHR.
    Scalbert E; Richer C; Giudicelli JF
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):94-104. PubMed ID: 2468942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
    Brogden RN; Sorkin EM
    Drugs; 1990 Dec; 40(6):903-49. PubMed ID: 2079001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.